Guangdong Tailai Runzhi Pharmaceutical Technology

Guangdong Tailai Runzhi Pharmaceutical Technology is a China-based pharmaceutical technology company engaged in the development and clinical evaluation of generic small molecule therapeutics. The company focuses on establishing therapeutic equivalence and pharmacokinetic profiles for domestically manufactured drug formulations. Notably, the company has sponsored and funded a randomized, open-label, crossover bioequivalence study in healthy Chinese volunteers to evaluate its 600 mg N-acetylcysteine (NAC) tablets against a reference formulation under both fasting and fed conditions. Through these clinical development efforts, Guangdong Tailai Runzhi Pharmaceutical Technology aims to advance affordable and high-quality respiratory and antioxidant treatments within the Chinese healthcare market.